He had his prostate removed by a robot. “All clear,” they said. Years later, his PSA started rising again. If the prostate was gone — how could the cancer be back?

In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, tells the story of Frank, a 59-year-old patient who underwent robotic-assisted prostatectomy believing it was the cure. But when his PSA began climbing, he discovered what most men never hear: surgery removes tissue, not necessarily the cancer or its root causes.

Dr. Prato explains how deep mapping (DNA, RNA, and immune spatial biology) can detect micro-metastases long before imaging or PSA changes. He reveals why circulating tumor cells (CTCs) and methylation testing are critical for detecting early spread — and how interventional oncology and custom immunotherapy can eliminate cancer without the devastating side effects of repeat surgeries or radiation.

🎯 What You’ll Learn in This Episode:
• Why prostate surgery often fails to eliminate micro-metastatic cancer
• How CTCs and methylation testing detect recurrence earlier than PSA
• What deep mapping and spatial biology reveal about hidden resistance
• How interventional oncology targets tumors without harming healthy tissue
• Why immunotherapy and NK cells are crucial for durable remission
• How adaptive monitoring keeps cancer in check long-term

📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: www.envita.com
📞 Speak to a care coordinator: 866-830-4576

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493